Author Interviews, Cancer Research, Case Western, Colon Cancer, JAMA / 07.12.2023
Case Western Study Finds GLP-1 Drugs Reduced Incidence of Colorectal Cancer
MedicalResearch.com Interview with:
Nathan A. Berger, M.D.
Distinguished University ProfessorProfessor, Biomedical Informatics
Director, Center for Artificial Intelligence in Drug Discovery
Case Western Reserve University School of Medicine
MedicalResearch.com: What is the background for this study?
Response: 75% of the US Population has overweight or obesity and 15% has Type 2 Diabetes.
Both overweight/obesity and diabetes promote increased incidence and worse prognosis of colorectal cancer.
The new GLP1RA drug class are rapidly becoming the most effective treatment for both diabetes and overweight/obesity.
By controlling diabetes and overweight/obesity, we hypothesized that the GLP1RAs might be effective at reducing incidence of colorectal cancer.
(more…)
Hanna-Payne Professor of Experimental Medicine Professor of Medicine, Biochemistry, Oncology and Genetics Director, Center for Science, Health and Society Case Western Reserve University School of Medicine
Rong Xu, PhD